Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical application of iridoid glycoside compound

A compound and application technology, applied in the direction of medical preparations containing active ingredients, pharmaceutical formulations, applications, etc.

Pending Publication Date: 2021-11-19
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no patent publication about the therapeutic effect of genipin 1-β-D-gentiobioside on non-alcoholic fatty liver disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of iridoid glycoside compound
  • Medical application of iridoid glycoside compound
  • Medical application of iridoid glycoside compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Genipin 1-β-D-gentiobioside anti-inflammatory and lipid-lowering experiments in vitro

[0074] 1. Experiments and methods

[0075] 1.1 Cell culture and administration method

[0076] Human liver cancer cell line HepG2 was inoculated into 6-well plates (density about 1×10 5 / ml), placed at 37°C, 5% CO 2 , 95% humidity in an incubator for 24 hours, divided into normal control group, model group and genipin 1-β-D gentiobioside group, 4 wells in each group. The normal control group was given DMEM medium, and the model group added FFA (oleic acid 0.3mM: palmitic acid 0.15mM) in the DMEM medium; 0.3 mM: palmitic acid (0.15 mM) and genipin 1-β-D gentiobioside (100 μM) were co-incubated, and after 24 hours of incubation, the cells were collected.

[0077] 1.2 Determination of TG

[0078] Aspirate the 12-well plate culture medium, wash (0.5ml / well) with PBS, (200μl / well) trypsinize for 3min; dilute to 800μl / well with PBS, pipette each well, then draw the liquid into the EP ...

Embodiment 2

[0110] In vivo efficacy experiment of genipin 1-β-D gentiobioside and geniposide on non-alcoholic fatty liver disease

[0111] 1. Experimental method

[0112] 1.1. Experimental materials

[0113] Fifty male 4-week-old C57 mice were purchased from Shanghai Slack Experimental Animal Center, and were bred in the SPF feeding room of the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine; the high-fat feed and its control feed were purchased from RESEARCH DIEATS Company, the item numbers are D12331 and D12328 , fructose and sucrose were purchased from Nantong Trofee Company, all with irradiation certificates. Genipin 1-β-D gentiobioside is isolated and purified from Gardenia jasmine by Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and its purity is >98%. Dangfei Liganning was purchased from Sichuan Meidakang Pharmaceutical Co., Ltd., the batch number is Z51020085.

[0114] 1.2. Animal modeling, grouping and administration

[0...

Embodiment 3

[0130] Inhibition of NLRP3 by genipin 1-β-D-gentiobioside in vivo and in vitro

[0131] 1. Experiments and methods

[0132] (In vivo pre-test animals and modeling are the same as above)

[0133] 1.1 Cell culture and administration method

[0134] Mouse normal liver cell line AML-12 was inoculated into 6-well plate (density about 1×10 5 / ml), placed at 37°C, 5% CO 2 , in an incubator with 95% humidity for 24 hours, divided into normal control group (Con), model group (FFA) and genipin 1-β-D gentiobioside group (FFA+GG), 4 wells in each group . The normal control group was given DMEM medium, and the model group added FFA (oleic acid 0.3mM: palmitic acid 0.15mM) in the DMEM medium; 0.3 mM: palmitic acid (0.15 mM) and genipin 1-β-D gentiobioside (100 μM) were co-incubated, and after 24 hours of incubation, the cells were collected.

[0135] 1.2 RNA sample preparation and quality analysis

[0136] ① Discard the supernatant after the incubation, wash the cells twice with PBS,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medical application of an iridoid glycoside compound, and particularly relates to an application of genipin 1-beta-D gentiobioside. The genipin 1-beta-D gentiobioside has the advantages that the expression of triglyceride TG and inflammation related genes TNF-alpha and IL-6 on in-vitro cells is obviously reduced; the content of animal serum ALT and liver TG on a non-alcoholic fatty liver model mouse induced by high fat and high glucose is reduced; and the expression of NLRP3 related genes can be inhibited in vivo and in vitro. Therefore, the genipin 1-beta-D gentiobioside can be used for preparing the medicine and other products for preventing and treating the non-alcoholic fatty liver disease.

Description

technical field [0001] The invention belongs to the field of medicine and health products, and specifically relates to the application of genipin 1-beta-D gentiobioside in the preparation of medicines, health products and other products for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Background technique [0002] Nonalcoholic fatty liver disease (Nonalcoholic Fatty Liver Disease, NAFLD) refers to a metabolic disease characterized by excessive deposition of fat in liver cells caused by alcohol and other clear liver damage factors. About 1 / 4 of the world's NAFLD will become the number one chronic liver disease in my country. However, the prevention and treatment of NAFLD still lacks ideal therapeutic drugs, and the US FDA has not yet approved any new drug for the treatment of NAFLD. At present, the specific pathogenesis of NAFLD has not yet been clarified , studies have found that it is related to various factors such as insulin resistance, oxidati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P1/16A61P29/00A61P35/00A23L33/125
CPCA61K31/7048A61P1/16A61P29/00A61P35/00A23L33/125A23V2002/00A23V2200/32A23V2250/21
Inventor 黄成钢胡义扬冯琴田小亭李志雄彭景华孙兆林徐洲赵瑜
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com